TRAIL therapy and prospective developments for cancer treatment

Area of Science:

• Immunology
• Molecular Biology
• Oncology

Background:

• Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) is a cytokine that selectively induces apoptosis in cancer cells.
• TRAIL activates apoptosis through death receptors (TRAIL-R1/DR4, TRAIL-R2/DR5) and the death-inducing signaling complex (DISC).
• This mechanism is particularly relevant for p53-mutated cancers, offering a p53-independent apoptotic pathway.

Purpose of the Study:

• To review emerging strategies for enhancing TRAIL-based cancer therapeutics.
• To address the limitations of current TRAIL therapies, including resistance and poor pharmacokinetics.
• To explore novel technologies for rejuvenating TRAIL therapeutics in clinical settings.

Main Methods:

• Review of scientific literature on TRAIL therapy.
• Analysis of protein modification, combinatorial approaches, and gene therapy strategies.
• Evaluation of recent technologies aimed at improving TRAIL efficacy.

Main Results:

• Recombinant TRAIL (rhTRAIL) and TRAIL-receptor agonist monoclonal antibodies (mAbs) have shown limited efficacy due to resistance and pharmacokinetic issues.
• Various strategies are being explored to enhance TRAIL's half-life, bioavailability, and potency.
• These approaches aim to sensitize resistant cancer cells to TRAIL-induced apoptosis.

Conclusions:

• Enhanced TRAIL therapy holds significant potential for cancer treatment.
• Overcoming resistance and improving drug delivery are key challenges.
• Continued research and technological advancements are crucial for clinical success.